v3.26.1
Segment Information (Details)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Reporting [Abstract]            
Number of operating segments | segment         1  
Revenue:            
Total revenue $ 187,546       $ 340,001 $ 4,255
Total revenue     $ (21,172)      
Cost of revenues 319,889   0   562,214 0
Indirect costs:            
Total research and development 241,966   1,428,762   902,428 3,726,143
Selling, general and administrative 2,593,671   2,377,866   4,842,237 4,687,030
Total operating expenses 2,835,637   3,806,628   5,744,665 8,413,173
Loss from operations (2,967,980)   (3,827,800)   (5,966,878) (8,408,918)
Other income, net (14,793)   (188,683)   (15,784) 14,128
Net loss (2,982,773) $ (2,999,889) (4,016,483) $ (4,378,307) (5,982,662) (8,394,790)
Research and development services and royalty revenue            
Revenue:            
Total revenue 187,546       340,001 4,255
Total revenue     (21,172)      
Reportable Segment            
Revenue:            
Total revenue 187,546       340,001 4,255
Total revenue     (21,172)      
Cost of revenues 319,889   0   562,214 0
Direct program costs:            
Contra-R&D expenses (4,017,949)   (3,780,794)   (7,087,095) (6,399,167)
Total research and development direct program costs 910,161   2,117,300   1,973,625 4,734,339
Indirect costs:            
Contra R&D expenses (698,849)   (759,000)   (1,130,697) (1,207,392)
Total research and development indirect costs (668,195)   (688,538)   (1,071,197) (1,008,196)
Total research and development 241,966   1,428,762   902,428 3,726,143
Selling, general and administrative 2,593,671   2,377,866      
Total operating expenses 2,835,637   3,806,628   5,744,665 8,413,173
Loss from operations (2,967,980)   (3,827,800)   (5,966,878) (8,408,918)
Net loss (2,982,773)   (4,016,483)   (5,982,662) (8,394,790)
Contra-R&D expenses 4,017,949   3,780,794   7,087,095 6,399,167
Reportable Segment | Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment            
Indirect costs:            
Interest expense 190,965   268,532   390,359 402,583
Interest income (176,145)   (69,847)   (367,833) (226,469)
Other income, net 27   10,002   6,742 190,242
Reportable Segment | Research and development services and royalty revenue            
Revenue:            
Total revenue 187,546       340,001 4,255
Total revenue     (21,172)      
Reportable Segment | Ovaprene            
Direct program costs:            
Direct program costs: 843,503   1,316,372   2,075,263 2,812,101
Contra-R&D expenses (800,000)   (400,000)   (1,700,000) (900,000)
Indirect costs:            
Contra-R&D expenses 800,000   400,000   1,700,000 900,000
Reportable Segment | Sildenafil Cream            
Direct program costs:            
Direct program costs: 134,769   49,881   202,560 261,270
Reportable Segment | Other advanced clinical stage programs            
Direct program costs:            
Direct program costs: 1,244,028   975,489   1,619,791 1,466,051
Contra-R&D expenses (1,300,000)   (1,000,000.0)   (1,800,000) (1,500,000)
Indirect costs:            
Contra-R&D expenses 1,300,000   1,000,000.0   1,800,000 1,500,000
Reportable Segment | Phase 1 and Phase 1-ready clinical stage programs            
Direct program costs:            
Direct program costs: 164,068   628,595   260,123 1,125,342
Contra-R&D expenses 0   (100,000)   0 (200,000)
Indirect costs:            
Contra-R&D expenses 0   100,000   0 200,000
Reportable Segment | Preclinical stage programs            
Direct program costs:            
Direct program costs: 1,457,723   1,718,320   2,626,102 2,767,058
Contra-R&D expenses (1,900,000)   (2,200,000)   (3,600,000) (3,800,000)
Indirect costs:            
Contra-R&D expenses 1,900,000   2,200,000   3,600,000 3,800,000
Reportable Segment | Personnel-related (including stock-based compensation)            
Indirect costs:            
Indirect costs: 1,084,019   1,209,437   2,276,881 2,701,684
Reportable Segment | Other indirect costs            
Indirect costs:            
Indirect costs: $ 30,654   $ 70,462   $ 59,500 $ 199,196